1,836.80
+2.90%
Close of 9 Nov 2026, in INR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Sai Life Sciences
Its shares trade on NSE under the ticker SAILIFE.NS. It has been listed since 18 December 2024. In the fiscal year to 31 March 2026, it reported revenue of ₹21.92bn and net income of ₹3.49bn. At that date it held total assets of ₹36.26bn and shareholders' equity of ₹24.84bn.
Sai Life Sciences Ltd is a IN-based company operating in Life Sciences Tools & Services industry. The company is headquartered in Hyderabad, Telangana. The company went IPO on 2024-12-18. Sai Life Sciences Limited is an India-based contract research, development, and manufacturing organization (CRO/CDMO). The firm carries out contract research and manufacturing activities for customers engaged in pharmaceutical and biotechnology industries. The company is engaged in offering a range of services tailor-made to the customer's requirements. The company provides discovery and chemistry, manufacturing, and controls (CMC) services that span from drug discovery to process development and early-phase supplies, all the way to commercial launch and life cycle management. Its services include Integrated Drug Discovery, Synthetic & medicinal chemistry, Biology, drug metabolism and pharmacokinetics (DMPK), Genotoxicity, General Toxicology and Computational chemistry. Its CMC services include route scouting; process development; analytical development; process safety; stability studies; early and mid-phase supplies; late phase, commercial manufacturing; technology transfer, and technologies.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Life Sciences Tools & Services
- Listed since
- 18 Dec 2024
- Website
- sailife.com ↗
Leadership
Pay as last reported
- Mr. Kanumuri RajuExecutive Chairman of the Board, since 1999₹29.1m
- Mr. Krishnam KanumuriChief Executive Officer, Managing Director, since 2016₹62.0m
- Mr. Sivaramakrishnan ChittorAdditional Whole-Time Director and Chief Financial Officer, since 2009₹43.7m
- Ms. Runa KaranChief Compliance Officer, Company Secretary₹3.6m
- Dr. Ramesh IyerIndependent Director₹4.8m
- Dr. Dinesh PatelAdditional Independent Director
- Ms. Suchita SharmaIndependent Director₹4.6m
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Sai Life Sciences Ltd operates in Hyderabad, Telangana, with a strong focus on Life Sciences Tools & Services.
- The company offers integrated drug discovery and CMC services spanning from drug discovery to commercial launch.
- Sai Life Sciences provides tailored services including synthetic chemistry, DMPK, and toxicology for pharmaceutical clients.
Weaknesses
- The company's IPO listing date of 18 December 2024 is a future event, not a current weakness.
- Sai Life Sciences is limited to the Indian market for its headquarters and operations.
- The company's services are primarily focused on pharmaceutical and biotechnology industries, which may limit diversification.
Opportunities
- Sai Life Sciences can expand its CMC services to include late-phase commercial manufacturing for global clients.
- The growing demand for biotechnology services in India presents a significant opportunity for the company.
- The company's integrated drug discovery services can attract new clients in the pharmaceutical sector.
Threats
- The company's reliance on the Indian market may pose risks due to regional economic fluctuations.
- Sai Life Sciences faces competition from global CRO/CDMO firms in the Life Sciences Tools & Services industry.
- The future IPO date of 18 December 2024 could introduce market volatility during the listing period.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.